Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

54
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
54
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

332
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
332
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

311
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
311
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

292
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
292
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A natural experiment during lockdown and on-going care-home COVID-19 outbreaks showed a single dose of vaccine reduced hospitalisation and deaths of care-home residents in North West England.

Public health·2024
Same author

Community-level variation in TB testing history in Blantyre, Malawi.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2024
Same author

Missed opportunities for diagnosis and treatment in patients with TB symptoms: a systematic review.

Public health action·2022
Same author

Does tuberculosis screening improve individual outcomes? A systematic review.

EClinicalMedicine·2021
Same author

Determining the value of TB active case-finding: current evidence and methodological considerations.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2021
Same author

Psychosocial and pharmacologic interventions for methamphetamine addiction: protocol for a scoping review of the literature.

Systematic reviews·2020

Related Experiment Video

Updated: Feb 27, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

657

The FDA just says yes

P MacPherson

    Hospitals & Health Networks
    |May 20, 1996
    PubMed
    Summary

    The accelerated Food and Drug Administration (FDA) approval process may increase healthcare costs and lead to rationing decisions. Faster drug approvals with less proof of long-term benefits raise concerns about patient care quality and financial burdens.

    Area of Science:

    • Health Policy
    • Pharmaceutical Regulation
    • Medical Economics

    Background:

    • The U.S. Food and Drug Administration (FDA) oversees drug approval.
    • Recent reforms aim to accelerate the FDA approval process for new medications.
    • Concerns exist regarding the potential impact of these reforms on patient care and healthcare costs.

    Purpose of the Study:

    • To evaluate the consequences of an accelerated FDA approval process on patient care.
    • To analyze the financial implications of faster drug market entry.
    • To explore the societal impact of increased healthcare costs and potential rationing.

    Main Methods:

    • Qualitative analysis of arguments surrounding FDA reform.
    • Review of economic models on drug pricing and healthcare expenditure.

    More Related Videos

    Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator
    07:06

    Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator

    Published on: May 14, 2020

    5.6K
    Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
    07:52

    Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

    Published on: September 10, 2018

    9.3K

    Related Experiment Videos

    Last Updated: Feb 27, 2026

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
    06:34

    Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

    Published on: November 29, 2024

    657
    Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator
    07:06

    Primary Clarification of CHO Harvested Cell Culture Fluid using an Acoustic Separator

    Published on: May 14, 2020

    5.6K
    Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
    07:52

    Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

    Published on: September 10, 2018

    9.3K
  • Ethical considerations of resource allocation in healthcare.

    • Main Results:

    • Arguments suggest accelerated FDA approval may lead to higher healthcare costs.
    • Concerns are raised about the long-term efficacy and safety of rapidly approved drugs.
    • Potential for difficult societal decisions regarding healthcare rationing due to increased costs.

    Conclusions:

    • The acceleration of the FDA approval process may have significant financial repercussions on patient care.
    • A trade-off may exist between speed of drug access and comprehensive evidence of long-term benefits.
    • Societal challenges, including healthcare rationing, may arise from the current trajectory of drug approval and associated costs.